Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m2 conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis
Abstract Background High-dose melphalan (HDMEL, 200 mg/m2) is considered as the standard conditioning regimen for autologous hematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma (MM). However, whether the combination of melphalan with busulfan (BUMEL) conditioning outperforms HDME...
Guardado en:
Autores principales: | Fei Gao, Mei-Si Lin, Jie-Shu You, Min-Yue Zhang, Long Cheng, Ke Lin, Peng Zhao, Qi-Yan Chen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bf86936891b348bb8ef2287932f17b2b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Autotrasplante (AT) de progenitores hematopoyéticos en mieloma múltiple: Experiencia clínica
por: Flores P,Claudio, et al.
Publicado: (2005) -
High-dose chemotherapy following autologous hematopoietic stem cell transplantation for multiple myeloma in the real world setting. Single-center experience
por: Nikita E. Mochkin, et al.
Publicado: (2020) -
Comparison of single and double autologous stem cell transplantation in multiple myeloma patients
por: Malkan Umit Yavuz, et al.
Publicado: (2021) -
Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma
por: Jiao Cai, et al.
Publicado: (2021) -
Autologous Hematopoietic Stem Cell Transplantation (AHSCT): An Evolving Treatment Avenue in Multiple Sclerosis
por: Mohammadi R, et al.
Publicado: (2021)